Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

United Therapeutics (UTHR) EPS (Basic) (2016 - 2026)

United Therapeutics' EPS (Basic) history spans 17 years, with the latest figure at $8.37 for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 24.74% to $8.37 in Q4 2025 year-over-year; TTM through Dec 2025 was $30.14, a 14.08% increase, with the full-year FY2025 number at $30.13, up 13.96% from a year prior.
  • EPS (Basic) hit $8.37 in Q4 2025 for United Therapeutics, up from $7.73 in the prior quarter.
  • Over the last five years, EPS (Basic) for UTHR hit a ceiling of $8.37 in Q4 2025 and a floor of $0.63 in Q1 2021.
  • Historically, EPS (Basic) has averaged $5.21 across 5 years, with a median of $5.42 in 2022.
  • Biggest five-year swings in EPS (Basic): crashed 79.94% in 2021 and later skyrocketed 742.86% in 2022.
  • Tracing UTHR's EPS (Basic) over 5 years: stood at $2.48 in 2021, then rose by 14.52% to $2.84 in 2022, then skyrocketed by 61.97% to $4.6 in 2023, then skyrocketed by 45.87% to $6.71 in 2024, then rose by 24.74% to $8.37 in 2025.
  • Business Quant data shows EPS (Basic) for UTHR at $8.37 in Q4 2025, $7.73 in Q3 2025, and $6.86 in Q2 2025.